MacDonald Laura, Murty Mano, Foster Brian C
Therapeutic Products Directorate Health Canada, Holland Cross, Tower B, Ottawa, Ontario, Canada.
Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):563-78. doi: 10.1517/17425250902942302.
The HIV/AIDS patient population is known to use natural health products (NHPs) in addition to the several antiretroviral drugs that constitute the treatment regimen for this disease. This review focuses on NHPs and their potential for interactions with antiretroviral agents resulting in therapeutic alterations or resistance. There are conflicting published medical literature reports and very few well-documented human clinical studies that unequivocally demonstrate if this concomitant use increases the risk of interaction/adverse reaction with these therapeutic products. This article outlines some findings from the Canadian domestic adverse reaction case reports associated with the use of antiretrovirals and NHPs. These adverse reaction case reports were specifically examined for patients taking NHPs together with their highly active antiretroviral therapy during or around the time when the adverse reaction developed. Together, the case reports and limited human clinical studies suggest that the risk for therapeutic alterations and resistance can exist due to changes in pharmacokinetic parameters with concomitant use of these therapeutic products.
众所周知,艾滋病毒/艾滋病患者群体除了使用构成该疾病治疗方案的几种抗逆转录病毒药物外,还会使用天然健康产品(NHPs)。本综述聚焦于天然健康产品及其与抗逆转录病毒药物相互作用的可能性,这种相互作用可能导致治疗效果改变或产生耐药性。关于这方面,已发表的医学文献报告相互矛盾,而且很少有记录完善的人体临床研究能明确证实这种联合使用是否会增加与这些治疗产品发生相互作用/不良反应的风险。本文概述了加拿大国内与使用抗逆转录病毒药物和天然健康产品相关的不良反应病例报告中的一些发现。这些不良反应病例报告专门针对在不良反应发生期间或前后同时服用天然健康产品和高效抗逆转录病毒疗法的患者进行了检查。病例报告和有限的人体临床研究共同表明,由于这些治疗产品联合使用会导致药代动力学参数发生变化,因此存在治疗效果改变和产生耐药性的风险。